Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies
International Journal of Molecular Sciences · 28.02.2025 · 26 (5) · 2196
DOI: 10.3390/ijms26052196 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.02.2025. Verfasst von Paschalis Karakasis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, Medical School, Hippokration General Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54124 Th…. Hauptthemen laut MEDLINE: Atherosclerosis, Diabetes Mellitus, Type 2, Diabetes Mellitus. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
The global rise in diabetes prevalence has significantly contributed to the increasing burden of atherosclerotic cardiovascular disease (ASCVD), a leading cause of morbidity and mortality in this population. Diabetes accelerates atherosclerosis through mechanisms such as hyperglycemia, oxidative stress, chronic inflammation, and epigenetic dysregulation, leading to unstable plaques and an elevated risk of cardiovascular events. Despite advancements in controlling traditional risk factors like dyslipidemia and hypertension, a considerable residual cardiovascular risk persists, highlighting the need for innovative therapeutic approaches. Emerging treatments, including sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, epigenetic modulators, and RNA-based therapies, are showing promise in addressing the unique challenges of diabetes-associated ASCVD. Precision medicine strategies, such as nanoparticle-based drug delivery and cell-specific therapies, offer further potential for mitigating cardiovascular complications. Advances in multiomics and systems biology continue to deepen our understanding of the molecular mechanisms driving diabetes-associated atherosclerosis. This review synthesizes recent advances in understanding the pathophysiology and treatment of diabetes-related atherosclerosis, offering a roadmap for future research and precision medicine approaches to mitigate cardiovascular risk in this growing population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Cardiology, Medical School, Hippokration General Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54124 Thessaloniki, Greece.
- First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 15772 Athens, Greece.
- Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Paschalis Karakasis, Panagiotis Theofilis, Dimitrios Patoulias, Panayotis K Vlachakis, Antonios P Antoniadis, Nikolaos Fragakis
Zitieren
APA
Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P. K., Antoniadis, A. P., & Fragakis, N. (2025). Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies. International Journal of Molecular Sciences, 26(5), 2196. https://doi.org/10.3390/ijms26052196
Vancouver
Karakasis P, Theofilis P, Patoulias D, Vlachakis PK, Antoniadis AP, Fragakis N. Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies. International Journal of Molecular Sciences. 2025;26(5):2196. doi:10.3390/ijms26052196
BibTeX
@article{Karakasis2025,
author = {Karakasis, Paschalis and Theofilis, Panagiotis and Patoulias, Dimitrios and Vlachakis, Panayotis K and Antoniadis, Antonios P and Fragakis, Nikolaos},
title = {Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {5},
pages = {2196},
doi = {10.3390/ijms26052196}
}
EUVIMED